Market Outlook Snapshot Market Dynamics Regional Forecast Country Insights Segment Analysis Competitive Landscape Industry News report.faq_name
On This Report

Contraceptive Drugs and Devices Market Size & Growth Forecast 2026–2035, By Segments (Product), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Report ID: FBI 11134| Published Date: Mar-2026| Format: PDF, Excel
MARKET OUTLOOK

Market Size and Growoth Outlook

Contraceptive Drugs and Devices Market size was around USD 32.42 Billion in 2025 and is slated to grow at a 6.1% CAGR from 2026 to 2035, surpassing USD 58.61 Billion by 2035. The industry revenue for 2026 is assessed at USD 34.14 billion.

Base Year Value (2025)
USD 32.42 Billion
CAGR (2026-2035)
6.1%
Forecast Year Value (2035)
USD 58.61 Billion
Historical Data Period
2022-2025
Largest Region
North America
Forecast Period
2026-2035

Get more details on this report

Request Free Sample Report
SNAPSHOT

Contraceptive Drugs and Devices Market Intelligence Snapshot

Regional Market Dynamics

  • North America leads due to broad product availability, established prescribing and retail channels, mature healthcare systems, and routine use of short- and long-acting contraceptive options.
  • Asia Pacific grows at 6.89% CAGR driven by rising family planning awareness, improving healthcare access, expanding contraceptive availability, and stronger pharmacy and counseling services across urban and semi-urban regions.

Segment Momentum

  • Contraceptive Devices hold a 66.54% share due to long-acting, procedure-based effectiveness and reduced reliance on daily adherence, making them widely preferred in routine contraceptive care settings.
  • Growth is driven by increasing preference for reliable, convenient, long-acting methods that reduce user dependency and align with evolving healthcare priorities for consistent and low-maintenance contraception.

Market Expansion Drivers

  • Rising global focus on reproductive health awareness and family planning programs driving adoption.
  • Increasing preference for long-acting reversible contraceptives improving compliance and effectiveness.
  • Expanding government-led contraception access initiatives improving affordability in developing regions.

Leading Market Participants

FORECAST SNAPSHOT

Global Market Forecast Snapshot

Market Outlook

Top players in the contraceptive drugs and devices market include Bayer AG (Germany), Organon & Co. (United States), Pfizer Inc. (United States), AbbVie Inc. (United States), Viatris Inc. (United States), Johnson & Johnson (United States), Church & Dwight Co., Inc. (United States), Veru Inc. (United States), Cupid Limited (India), Agile Therapeutics, Inc. (United States).

Regional and Segment Outlook

North America
MARKET DYNAMICS

Market Growth Drivers and Industry Trends

Rising global focus on reproductive health awareness and family planning programs driving adoption

As public health agencies, NGOs, and healthcare providers place greater emphasis on reproductive health education, the contraceptive drugs and devices market benefits from a broader shift in consumer behavior from reactive pregnancy prevention to planned, informed contraceptive use. Family planning programs improve awareness of available methods, reduce stigma around discussing contraception, and bring first-time users into clinical settings where counseling often leads to method selection based on lifestyle, safety, and duration needs. This raises prescription volumes for hormonal products while also supporting uptake of provider-administered devices, driving market development through higher conversion from awareness to actual product use.

Increasing preference for long-acting reversible contraceptives improving compliance and effectiveness

A growing tilt toward long-acting reversible contraceptives is reshaping the contraceptive drugs and devices market by favoring products that reduce user error and limit the need for frequent refills or daily adherence. In practice, clinicians and patients increasingly prioritize methods such as intrauterine devices and implants because their duration and reliability improve continuation rates compared with short-cycle options. That preference influences procurement patterns, provider training, and product mix, with demand moving toward higher-value device categories that support market expansion through sustained usage and lower discontinuation linked to missed doses or inconsistent compliance.

Expanding government-led contraception access initiatives improving affordability in developing regions

Public-sector contraception programs are increasing market penetration in lower-income countries by reducing out-of-pocket costs and widening distribution beyond urban private clinics. When governments subsidize products, integrate contraceptives into primary care systems, and include them in national reproductive health campaigns, the contraceptive drugs and devices market gains access to large populations that previously faced affordability and availability barriers. These initiatives also create more predictable institutional purchasing channels, encouraging manufacturers and distributors to strengthen local supply networks and support broader product availability where unmet need has historically constrained demand.

Growth Driver Impact on CAGR Regulatory Influence Geographic Relevance Adoption Rate Impact Timeline
Rising global focus on reproductive health awareness and family planning programs driving adoption 2.30% High Asia Pacific, Africa, North America High Near Term
Increasing preference for long-acting reversible contraceptives improving compliance and effectiveness 2.00% High North America, Europe High Mid Term
Expanding government-led contraception access initiatives improving affordability in developing regions 1.80% High Asia Pacific, Latin America, Africa High Mid Term
CUSTOM RESEARCH

Unlock insights tailored to your business with our bespoke market research solutions.

Click to get your customized report now.

Request Customization →
REGIONAL FORECAST

Regional Demand Dynamics

Polymer Modified Bitumen Market
Largest Region
North America
XX% Market Share in 2025
North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the largest regional share of the contraceptive drugs and devices market in 2025, bolstered by broad product availability, established prescribing and retail distribution channels, and consistent use of both short-term and long-acting contraceptive options. The region’s leadership is reinforced by mature healthcare systems, higher awareness of reproductive health management, and routine interaction between patients, physicians, clinics, and pharmacies, which keeps product uptake steady across branded and generic categories.

Asia Pacific is projected to expand at a 6.89% CAGR over the forecast period, with growth in the contraceptive drugs and devices market being propelled by rising awareness of family planning, improving access to healthcare services, and wider availability of modern contraceptive products across urban and semi-urban settings. Adoption is accelerating as healthcare outreach, pharmacy access, and clinical counseling improve practical access to contraceptive choices, while a large population base continues to translate these improvements into stronger regional demand.

Parameter North America Asia Pacific Europe Latin America MEA
Innovation Hub i Scale Nascent Developing Advanced
Cost-Sensitive Region i Scale Low Medium High
Regulatory Environment i Scale Restrictive Neutral Supportive
Demand Drivers i Scale Weak Moderate Strong
Development Stage i Scale Emerging Developing Developed
Adoption Rate i Scale Low Medium High
New Entrants / Startups i Scale Sparse Moderate Dense
Macro Indicators i Scale Weak Stable Strong
COUNTRY INSIGHTS

Key Country Insights

Germany 🇩🇪

Preventive Healthcare Integration

Germany integrates contraceptive drugs and devices into established reproductive healthcare services with an emphasis on informed clinical guidance. The market supports demand for reliable, evidence-based contraceptive solutions tailored to individual patient needs and long-term reproductive planning.

France 🇫🇷

Public Health Accessibility

France supports the contraceptive drugs and devices market through established reproductive health programs and preventive healthcare initiatives. Demand remains focused on accessible contraceptive options, consistent clinical support, and product innovation that enhances patient convenience and adherence.

Italy 🇮🇹

Clinical Care Alignment

Italy emphasizes contraceptive drugs and devices within gynecological care and family planning services. Healthcare providers increasingly recommend personalized contraceptive approaches that balance effectiveness, patient preferences, and long-term reproductive health management.

Japan 🇯🇵

Patient-Centered Adoption

Japan continues expanding awareness and clinical use of modern contraceptive drugs and devices through evolving reproductive healthcare practices. Healthcare professionals focus on improving patient education, treatment suitability, and access to contraceptive options that align with individual preferences.

South Korea 🇰🇷

Expanding Reproductive Care

South Korea is strengthening access to contraceptive drugs and devices through increasing awareness of reproductive health and preventive care. Market participants prioritize innovative product offerings and patient engagement strategies that support informed contraceptive decision-making across different age groups.

United States 🇺🇸

Comprehensive Product Access

The U.S. contraceptive drugs and devices market is characterized by broad product availability across prescription and over-the-counter categories. Healthcare providers continue emphasizing patient choice, long-acting contraceptive options, and expanded access through diverse clinical and retail distribution channels.

SEGMENT ANALYSIS

Segment Leadership and Growth Trends

Contraceptive Drugs and Devices Market Share (%), Product, 2025

Contraceptive Devices
Contraceptive Drugs

Go beyond the chart, access full insights & data tables

Request Free Sample Report
Product Segment Analysis: Contraceptive Devices (Largest & Fastest-Growing Segment)

Contraceptive Devices held a 66.54% share of the contraceptive drugs and devices market in 2025, reflecting their established position in routine family planning and clinical contraceptive care. Their leadership is maintained through practical use patterns that favor longer-acting and procedure-based options where adherence is less dependent on daily user behavior, which supports continued adoption across healthcare settings. The same operating advantage is also driving growth in the contraceptive drugs and devices market, as users and providers increasingly prefer methods that combine reliability, convenience, and reduced need for frequent intervention compared with short-cycle pharmaceutical alternatives.

Segment Sub-Segment Largest Segment Fastest Growing
Product Contraceptive Drugs, Contraceptive Devices Contraceptive Devices Contraceptive Devices
Competitive Landscape

Competitive Landscape and Market Positioning

Major players in the contraceptive drugs and devices market:

1. Bayer AG (Germany)

2. Organon & Co. (United States)

3. Pfizer Inc. (United States)

4. AbbVie Inc. (United States)

5. Viatris Inc. (United States)

6. Johnson & Johnson (United States)

7. Church & Dwight Co. Inc. (United States)

8. Veru Inc. (United States)

9. Cupid Limited (India)

10. Agile Therapeutics Inc. (United States)

Growing focus on reproductive healthcare and family planning is reshaping the contraceptive drugs and devices market. Market activity is centered around the development of user-friendly products with improved safety profiles and long-term effectiveness. Continuous innovation in delivery systems and formulations, combined with rising awareness regarding women’s healthcare options, is contributing to broader product adoption and stronger market penetration across multiple demographics.

Company Market Share Company Revenue Revenue CAGR (%) Product Portfolio Geographic Presence Innovation / R&D Focus Strategic Developments
No companies available.
🔒 This section is available as a standalone purchase. Buy only the data you need. Inquire Before Buying
Industry News

Industry Development/News

Company Name Date Key Development
China Government Jan-26 The Chinese government reinstated a 13% value-added tax on contraceptives and condoms, ending a three-decade-old exemption. This fiscal policy shift is a strategic effort to influence demographic trends and address declining national birth rates by increasing the cost and potentially reducing the accessibility of contraceptive products within the domestic market.
NEXT Life Sciences Mar-25 NEXT Life Sciences initiated clinical trials in Australia for Plan A, a reversible, non-hormonal male contraceptive system designed to occlude the vas deferens. This advancement represents a significant step in diversifying the male contraceptive landscape, addressing a long-standing market gap for long-acting, reversible options that shift reproductive health responsibility beyond traditional methods.
Femasys Mar-25 Femasys secured CE mark certification for its FemBloc delivery system, the first non-surgical permanent birth control device. This regulatory milestone provides a less invasive alternative to traditional tubal ligation, enabling in-office procedures that reduce surgical risks and recovery times, thereby expanding access to permanent contraception options in the European market.
Daré Bioscience Feb-25 Daré Bioscience and Theramex entered a co-development agreement for Casea S, a biodegradable, long-acting contraceptive implant. The device is designed to provide contraception for 18–24 months before dissolving, which eliminates the requirement for surgical removal and addresses a critical usability barrier associated with current long-acting reversible contraceptive implants.
Perrigo Mar-24 Perrigo commenced U.S. retail sales of Opill, the first daily oral contraceptive approved for over-the-counter access. By removing the requirement for a medical prescription, this market entry significantly lowers barriers to hormonal contraception, expanding the commercial reach of progestin-only pills to a broader consumer demographic through major retail and online pharmacy channels.
Ministry of Population and Family Development Indonesia Dec-24 The Indonesian Ministry of Population and Family Development successfully integrated its contraceptive supply information system with national family planning infrastructure. This digital transformation streamlines data management, improves the accuracy of inventory forecasting, and enhances the efficiency of distribution networks to ensure consistent supply chain reliability for contraceptive products across the country.
Report Customization

Explore This Report

Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.

1 report.custom report.segments 2 Custom TOC 3 Related Reports

Contraceptive Drugs and Devices Market — Custom Segments

Segment Sub-Segment
No segment data available.

Contraceptive Drugs and Devices Market — report.custom

Custom Chapter Custom Details
No custom TOC data available.

Need a different cut of the data?

Request Custom Research
report.faq_name

What is the current revenue of the contraceptive drugs and devices market?

In 2026 the market for contraceptive drugs and devices is valued at USD 34.14 billion.

What is the projected value of the contraceptive drugs and devices industry by 2035?

Contraceptive Drugs and Devices Market size is expected to advance from USD 32.42 billion in 2025 to USD 58.61 billion by 2035 registering a CAGR of more than 6.1% across 2026-2035.

How is rising reproductive health awareness influencing contraceptive adoption behavior globally?

Family planning programs and awareness initiatives are increasing informed contraceptive use, improving counseling uptake, and driving higher conversion from awareness to clinical adoption of both hormonal and device-based options.

How are long-acting contraceptive preferences and government initiatives reshaping market access and usage patterns?

Preference for long-acting reversible contraceptives improves compliance and continuation, while government-led subsidies and access programs expand affordability and distribution, significantly increasing adoption in underserved and developing regions.

Why do Contraceptive Devices dominate the market?

Contraceptive Devices hold a 66.54% share due to long-acting, procedure-based effectiveness and reduced reliance on daily adherence, making them widely preferred in routine contraceptive care settings.

What is driving growth within Contraceptive Devices?

Growth is driven by increasing preference for reliable, convenient, long-acting methods that reduce user dependency and align with evolving healthcare priorities for consistent and low-maintenance contraception.

Why is North America the leading region in the contraceptive drugs and devices market?

North America leads due to broad product availability, established prescribing and retail channels, mature healthcare systems, and routine use of short- and long-acting contraceptive options.

What is driving contraceptive market growth in Asia Pacific?

Asia Pacific grows at 6.89% CAGR driven by rising family planning awareness, improving healthcare access, expanding contraceptive availability, and stronger pharmacy and counseling services across urban and semi-urban regions.

Which companies are driving growth in the contraceptive drugs and devices landscape?

Top players in the contraceptive drugs and devices market include Bayer AG (Germany), Organon & Co. (United States), Pfizer Inc. (United States), AbbVie Inc. (United States), Viatris Inc. (United States), Johnson & Johnson (United States), Church & Dwight Co., Inc. (United States), Veru Inc. (United States), Cupid Limited (India), Agile Therapeutics, Inc. (United States).
Testimonials

Our Clients

"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."

Quality Assurance Manager

"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."

R&D Manager

"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."

Senior Marketing Manager
THE RESEARCH BEHIND THIS REPORT

Our Research Team & Methodology

Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.

THIS REPORT'S RESEARCH VERTICAL

Research Team Overview

♢
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.

Prepared by the Healthcare & Medical Devices Research Team

10+
Industry Verticals
100+
Countries Analyzed
5–7
Days Standard
Delivery
12k+
Research Reports
Published
On-
Demand
Customized Research
Available
6
Months Analyst
Support
PDF + XLS
Report Deliverables

Trust & Compliance

☷D&B D-U-N-S
♢GDPR & CCPA Compliant
♙ISO 9001 Certified (ISO 9001:2015)
♙SSL Encryption
▭Secure Payments
✓Confidential Handling

Research Domains

10 coverage areas
Medical Devices & Equipment Diagnostic Imaging Clinical Diagnostics Digital Health & Telemedicine Patient Monitoring Systems Surgical & Minimally Invasive Technologies Healthcare IT & Data Systems Biotechnology & Life Sciences Pharmaceutical Technologies Healthcare Delivery & Services

Research Intelligence

Executive Leadership
Product & Technology Experts
Manufacturing & Operations Leaders
Procurement & Supply Chain Professionals
Sales & Commercial Executives
Channel Partners & Distribution Networks
Enterprise Buyers & End Users
Industry Consultants & Regulatory Experts

Research Workflow & Quality Assurance

📥
01

Data Collection

Verified information gathered through primary and secondary research.

🔍
02

Data Triangulation

Cross-validation using multiple independent data sources.

📈
03

Forecast Modelling

Market estimates developed using historical trends and analytical models.

👨‍💼
04

Analyst Validation

Findings reviewed by domain experts for accuracy and consistency.

📝
05

Editorial & Quality Review

Final editorial, quality, and compliance checks before publication.

✅
06

Final Publication

Released after successful completion of the internal review process.

Report Coverage

📊 Market Assessment

  • Market Size & Forecast
  • Market Segmentation
  • Regional Analysis
  • Growth Drivers & Challenges
  • Market Dynamics

🏢 Competitive Intelligence

  • Competitive Landscape
  • Company Profiles
  • Competitive Benchmarking
  • Mergers & Acquisitions
  • Market Share Analysis or Key Company Strategies

🔍 Strategic Analysis

  • Value Chain Analysis
  • Porter's Five Forces
  • PESTLE Analysis
  • Pricing Trends
  • Supply-Demand Analysis

🚀 Future Outlook

  • Technology Landscape
  • Regulatory Landscape
  • Investment & Funding Landscape
  • Emerging Opportunities
  • Future Market Outlook

Have a question about this report or need a custom scope?

Request Customization
License

Select License Type

Single User
US$ 4,250
Buy Now
Corporate User
US$ 6,150
Buy Now

Want this data scoped to your exact question?

Tell us the segments, regions, or competitors you need answered — an analyst will confirm scope before any custom work starts.

Talk to an Analyst →